, Tracking Stock Market Picks
Enter Symbol:
Cadence Pharmaceuticals, Inc. (CADX) [hlAlert]

up 99.71 %

Cadence Pharmaceuticals, Inc. (CADX) rated Buy with price target $9 by Deutsche Bank

Posted on: Friday,  May 3, 2013  1:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) on 05/03/2013, when the stock price was $7.00. Since
then, Cadence Pharmaceuticals, Inc. has gained 99.71% as of 03/18/2014's recent price of $13.98.
If you would have followed this Deutsche Bank's recommendation on CADX, you would have gained 99.71% of your investment in 319 days.

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/3/2013 1:25 PM Buy
7.00 9.00
as of 12/13/2013
1 Week down  -5.87 %
1 Month up  59.60 %
3 Months up  56.54 %
1 YTD up  28.14 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy